This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kjøller-Hansen, L. Articles by Grande, P. Search for Related Content PubMed PubMed Citation Articles by Kjøller-Hansen, L. Articles by Grande, P.

The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES)

^a The Heart Center, Rigshospitalet, Copenhagen, Denmark

View larger version (11K): [in a new window]   Figure 1 Cardiac death, AMI, clinical heart failure or recurrent angina pectoris. Kaplan-Meier plot of time to first event for the quadruple-composite end point: cardiac death, AMI, heart failure or recurrent angina pectoris. Shown are the number of patients at risk in each treatment group at the beginning of each treatment year.

View larger version (11K): [in a new window]   Figure 2 Cardiac death, AMI or clinical heart failure. Kaplan-Meier plot of time to first event for the triple-composite end point: cardiac death, AMI or clinical heart failure. Shown are the number of patients at risk in each treatment group at the beginning of each treatment year.

View larger version (14K): [in a new window]   Figure 3 Secondary end points. Kaplan-Meier plot of time to: (a) cardiac death or AMI, (b) cardiac death or heart failure, (c) clinical heart failure and (d) recurrent angina pectoris.